Search
infliximab-dyyb (Inflectra, Remisima, CT-P13)
Biosimilar to infliximab. FDA-approved April 2016
Indications:
- Crohn's disease [4,5]
Notes:
- 2017 Medicare part D cost: $14,202/year, out of pocket $5118 [2]
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
infliximab (Remicade)
biosimilar
References
- FDA News Release. April 5, 2016
FDA approves Inflectra, a biosimilar to Remicade
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm
- Yazdany J, Dudley RA, Lin GA et al
Out-of-Pocket Costs for Infliximab and Its Biosimilar for
Rheumatoid Arthritis Under Medicare Part D.
JAMA. 2018;320(9):931-933
PMID: 30193264
https://jamanetwork.com/journals/jama/fullarticle/2698912
- McKeage K.
A review of CT-P13: an infliximab biosimilar.
BioDrugs. 2014 Jun;28(3):313-21. Review.
PMID: 24723086
- Schulze K Koppka N, Lutter F et al
CT-P13 (Inflectra>, Remsima) monitoring in patients
with inflammatory bowel disease.
Biologicals. Volume 44, Issue 5, Sept 2016, Pages 463-466
PMID: 27435444
- Meyer A, Rudant J, Drouin J et al.
Effectiveness and safety of reference infliximab and
biosimilar in Crohn Disease: A French equivalence study.
Ann Intern Med 2018 Dec 11;
PMID: 30534946
http://annals.org/aim/article-abstract/2718685/effectiveness-safety-reference-infliximab-biosimilar-crohn-disease-french-equivalence-study?